BPA SITAGLIPTIN TABLET (Beximco Pharmaceuticals Australia Pty Ltd)
Product name
BPA SITAGLIPTIN TABLET
Date registered
Evaluation commenced
Decision date
Approval time
132 working days (255)
Active ingredients
sitagliptin phosphate
Registration type
New generic medicine
Indication
BPA SITAGLIPTIN TABLE is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:
- monotherapy when metformin is considered inappropriate due to intolerance; or
- in combination with other anti-hyperglycaemic agents, including insulin,(see 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials, 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS for available data on different add-on combination therapies).